Product Information
DAYVIGO 5 MG TABLET is a brand product labeled by Eisai Inc., priced at $11.5776 per EA under NDC 62856040530. Its NADAC has been published 315 times since Sep 23, 2020.
FDA first approved this application on Apr 7, 2020.
Strength
5 mg/1
Manufacturer
Eisai Inc.NDC
62856040530
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
LEMBOREXANTApproval Type
New Drug (NDA)
FDA Application
NDA212028FDA Approved
4/7/2020
On Market Since
4/7/2020
Pharmacological Classes
Price Statistics
The NADAC for DAYVIGO 5 MG TABLET has been published 315 times since Sep 23, 2020, and over the history we have for it it has risen 31.8%. The table below summarizes its recorded NADAC range and movement.
| Current price | $11.5776 per EA |
|---|---|
| All-time high | $11.5839 (Jul 15, 2026) |
| All-time low | $8.7826 (Sep 23, 2020) |
| 52-week high | $11.5839 |
| 52-week low | $11.2308 |
| Median price | $10.1639 |
| Average price | $10.2678 |
| Largest weekly change | +8.2% (Jan 25, 2023) |
| Weeks tracked | 315 |
| Tracking since | Sep 23, 2020 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the lemborexant market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Eisai Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
lemborexant market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Orexin Receptor Antagonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DAYVIGO 5 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for DAYVIGO 5 MG TABLET, manufactured by Eisai Inc., is $11.5776 per EA (NDC 62856040530), effective Sep 30, 2026.
How has the price of DAYVIGO 5 MG TABLET changed over time?
Over the history we have for it, the NADAC for DAYVIGO 5 MG TABLET has risen 31.8%. It has been tracked across 315 weekly CMS publications since Sep 23, 2020.
What are the highest and lowest recorded NADAC prices for DAYVIGO 5 MG TABLET?
Since Sep 23, 2020, the NADAC for DAYVIGO 5 MG TABLET has ranged from a low of $8.7826 (Sep 23, 2020) to a high of $11.5839 (Jul 15, 2026), with a median of $10.1639 per EA.
Are there cheaper alternatives to DAYVIGO 5 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of DAYVIGO 5 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DAYVIGO 5 MG TABLET?
DAYVIGO 5 MG TABLET (NDC 62856040530) is labeled by Eisai Inc., and CMS classifies it as a brand product.